Article
CYP17 polymorphism as a risk factor of tamoxifen-induced hepatic steatosis in breast cancer patients.
Oncology reports - 1 Mar 2005
Ohnishi Takenao, Ogawa Yasuhiro, Saibara Toshiji, Nishioka Akihito, Kariya Shinji, Fukumoto Mitsutaka, Onishi Saburo, Yoshida Shoji
Abstract excerpt
Oral administration of tamoxifen, an endocrine therapy for breast cancer, often induces hepatic steatosis (THS, tamoxifen-induced hepatic steatosis) as a complication, which can progress to non-alcoholic steatohepatitis (NASH). The development of this complication is strongly associated with three clinical risk factors; specifically, insulin resistance, central obesity, and hypertriglyceridemia, however a genetic...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.